Regulated AI & Data Validation Engineering for Pharmaceutical Manufacturing
USP <665> became enforceable 1 May 2026. End users now bear regulatory responsibility for assessing Process Equipment-Related Leachables (PERLs) across their entire plastic manufacturing train. ASTM E3051-25 (January 2025) requires digital data management for SUS qualification and continued verification.
sus-cpv-sentinel -- Stage 3 Continued Process Verification for Single-Use Systems
- GAMP 5 Category 4 | Fully validated | 51 URS requirements | 39/39 test cases
- Cpk/Ppk per SKU | Shewhart I-MR | Hotelling T2 | Supplier SCN Scorecard
- ALCOA+-compliant SHA-256 hash-chained audit trail | 21 CFR Part 11
- Complete validation package: VP | URS | FMEA | IQ | OQ | PQ | RTM | VSR
- Kneat Gx execution | Veeva Vault QualityDocs document control
| Standard | Scope |
|---|---|
| FDA Process Validation (2011) Stage 3 | Continued Process Verification framework |
| ASTM E3051-25 (January 2025) | SUS digital data management and qualification |
| PDA Technical Report No. 66 | SUS E&L monitoring, supplier qualification |
| USP <665> (effective 1 May 2026) | PERL assessment, plastic manufacturing train |
| 21 CFR Part 11 / ALCOA+ | Electronic records, audit trail, data integrity |
| GAMP 5 Second Edition (2022) | Risk-based validation, Category 4 software |
| ICH Q9(R1) | FMEA-based quality risk management |
Closing the gap between pharmaceutical SUS process data, FDA Stage 3 CPV requirements, and regulatory audit readiness through validated, ALCOA+-compliant analytical platforms.
j-arndt.github.io -- Portfolio and interactive demos
linkedin.com/in/qualityai -- LinkedIn